ValuEngine cut shares of ChemoCentryx, Inc. (NASDAQ:CCXI) from a hold rating to a sell rating in a research note published on Saturday.
A number of other research analysts have also weighed in on CCXI. BidaskClub lowered ChemoCentryx from a buy rating to a hold rating in a report on Friday, August 18th. Zacks Investment Research lowered ChemoCentryx from a buy rating to a sell rating in a report on Friday, August 11th. Finally, Cowen and Company reissued a hold rating on shares of ChemoCentryx in a report on Tuesday, August 8th. One research analyst has rated the stock with a sell rating, three have given a hold rating and one has assigned a buy rating to the stock. The company has an average rating of Hold and an average target price of $9.00.
Shares of ChemoCentryx (CCXI) traded down 1.95% during midday trading on Friday, hitting $7.03. 140,361 shares of the stock traded hands. The firm’s 50 day moving average price is $7.50 and its 200 day moving average price is $7.83. The company’s market capitalization is $342.41 million. ChemoCentryx has a 12-month low of $5.52 and a 12-month high of $10.80.
ChemoCentryx (NASDAQ:CCXI) last posted its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.19) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.02). The company had revenue of $8.94 million during the quarter. Analysts expect that ChemoCentryx will post ($0.90) EPS for the current year.
COPYRIGHT VIOLATION WARNING: “ChemoCentryx, Inc. (CCXI) Downgraded by ValuEngine to Sell” was posted by Ticker Report and is the property of of Ticker Report. If you are accessing this piece on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark law. The correct version of this piece can be viewed at https://www.tickerreport.com/banking-finance/2977383/chemocentryx-inc-ccxi-downgraded-by-valuengine-to-sell.html.
A number of hedge funds and other institutional investors have recently modified their holdings of CCXI. Bank of Montreal Can acquired a new position in ChemoCentryx in the 2nd quarter valued at $102,000. JPMorgan Chase & Co. acquired a new position in ChemoCentryx in the 2nd quarter valued at $104,000. Voya Investment Management LLC grew its holdings in ChemoCentryx by 22.8% in the 2nd quarter. Voya Investment Management LLC now owns 15,984 shares of the biopharmaceutical company’s stock valued at $150,000 after buying an additional 2,965 shares in the last quarter. Trexquant Investment LP grew its holdings in ChemoCentryx by 81.1% in the 2nd quarter. Trexquant Investment LP now owns 18,600 shares of the biopharmaceutical company’s stock valued at $174,000 after buying an additional 8,327 shares in the last quarter. Finally, State of Wisconsin Investment Board acquired a new position in ChemoCentryx in the 2nd quarter valued at $178,000. 50.12% of the stock is currently owned by hedge funds and other institutional investors.
ChemoCentryx, Inc is a biopharmaceutical company. The Company is engaged in developing new medications targeted at inflammatory disorders, autoimmune diseases and cancer. Each of its drug candidates focuses on a specific chemoattractant receptor that selectively blocks its negative inflammatory or suppressive response, leaving the rest of the immune system intact.
Receive News & Ratings for ChemoCentryx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx Inc. and related companies with MarketBeat.com's FREE daily email newsletter.